Page 253 - HIVMED_v21_i1.indb

Page 2 of 2 Editorial

2. McIntyre JA, Hopley M, Moodley D, et al. Efficacy of short-course AZT plus 3TC to 5. Sinxadi PZ, Leger PD, McIlleron H, et al. Pharmacogenetics of plasma efavirenz
reduce nevirapine resistance in the prevention of mother-to-child HIV exposure in HIV-infected adults and children in South Africa. Br J Clin Pharmacol.
transmission: A randomized clinical trial. PLoS Med. 2009;6(10):e1000172. 2015;80(1):146–156. https://doi.org/10.1111/bcp.12590
https://doi.org/10.1371/journal.pmed.1000172
3. Ajibola G, Maruapula D, Rowley C, et al. ‘Drug resistance after cessation of efavirenz- 6. Treasure GC, Aga E, Bosch RJ, et al. Brief report: Relationship among viral
load outcomes in HIV treatment interruption trials. J Acquir Immune Defic
based antiretroviral treatment started in pregnancy. S Afr J HIV Med. 2020;21(1),
a1023. https://doi.org/10.4102/sajhivmed.v21i1.1023 Syndr. 2016;72(3):310–313. https://doi.org/10.1097/QAI.0000000 0000
00964
4. Jackson A, Moyle G, Watson V, et al. Tenofovir, emtricitabine intracellular and
plasma, and efavirenz plasma concentration decay following drug intake 7. Li JZ, Etemad B, Ahmed H, et al. The size of the expressed HIV reservoir predicts
cessation: Implications for HIV treatment and prevention. J Acquir Immune Defic timing of viral rebound after treatment interruption. AIDS. 2016;30(3):343–353.
Syndr. 2013;62(3):275–281. https://doi.org/10.1097/QAI.0b013e3 182829bd0 https://doi.org/10.1097/01.aids.0000499516.66930.89

http://www.sajhivmed.org.za 245 Open Access